Articles related to EVIDENCE REVIEW

Bausch + Lomb launched PreserVision AREDS3, a reformulation of its established AREDS2 supplement adding a proprietary B-vitamin complex, citing a narrative review of more than 20 human studies linking B-vitamin supplementation to reduced AMD risk.

A JAMA Psychiatry network meta-analysis ranked lumateperone highest for efficacy and aripiprazole highest for acceptability among five FDA-approved adjunctive atypical antipsychotics for major depressive disorder.

A systematic review of 27 studies found behavioral sleep interventions — particularly CBT-I and sleep hygiene — reduced BMI and body weight in adults with poor sleep health, with the largest effects among patients with obesity.

Two retina specialists debated whether LIGHTSITE III evidence supports photobiomodulation as treatment for intermediate dry AMD, weighing modest BCVA gains against natural visual acuity variability, study quality concerns, and FDA authorization status.

Three recent studies examined associations between vitamin D status and outcomes across type 2 diabetes risk, Alzheimer’s biomarkers, and inflammatory bowel disease in exploratory cohorts.

A systematic review of five studies found no consistent short-term safety signals in renal, hepatic, or cardiometabolic outcomes among adolescents using creatine monohydrate.